UBS cuts target for Alnylam Pharmaceuticals stock from USD 550.00 to USD 354.00

Published on 10/27/2026 at 21:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alnylam reports third-quarter results on October 29, 2026 after UBS kept Buy. Alnylam Pharmaceuticals stock costs EUR 203.70 on October 27, 2026.

UBS target cut and trial data

UBS cut its Alnylam target from USD 550.00 to USD 354.00 on October 15, 2026.
Brezosiran reduced mutant huntingtin by 60.00 to 64.00 percent at month three in Phase 1b data dated October 23, 2026.
Alnylam Pharmaceuticals stock costs EUR 203.70 at Lang & Schwarz on October 27, 2026 at 9:43 p.m. CEST.
Alnylam is scheduled to report third-quarter results on October 29, 2026.

Alnylam Pharmaceuticals, US02043Q1076, Illustration mit AI erstellt.

On October 15, 2026, UBS adjusted its Alnylam target from USD 550.00 to USD 354.00 and kept a Buy rating, as reported by MarketScreener. Alnylam Pharmaceuticals stock was quoted at EUR 203.70 at Lang & Schwarz on October 27, 2026 at 9:43 p.m. CEST.

Brezosiran delivers a measurable signal

Alnylam's strongest operating update came on October 23, 2026, when the company reported initial Phase 1b data for brezosiran in Huntington's disease. According to Alnylam, mutant huntingtin in cerebrospinal fluid fell by 60.00 to 64.00 percent at month three in the highest dose group evaluated, with an individual reduction of up to 83.00 percent. The study covered 48 participants across five dose cohorts, while a sixth cohort of 12 participants was enrolling.

The stock stays below its yearly high

On Nasdaq, Alnylam last traded at USD 226.79 on October 27, 2026 at 4:00 p.m. ET. The price stood 53.20 percent below the USD 484.61 52-week high and above the USD 197.81 low. Trading volume reached 1,603,173 shares, while the price-to-earnings ratio was 38.31 and market capitalization was USD 30.3 billion.

Results arrive on October 29

Alnylam is scheduled to report third-quarter 2026 financial results on October 29, 2026, before U.S. markets open, with an earnings conference call at 8:30 a.m. ET, according to MarketScreener. The report will give investors a fresh test of commercial growth after second-quarter revenue reached USD 1.29 billion, up 66.90 percent from the prior-year quarter, according to Yahoo Finance.

How the valuation compares

Alnylam's USD 30.3 billion market capitalization and 38.31 price-to-earnings ratio place the valuation firmly in the large-cap biotechnology group. Ionis Pharmaceuticals traded at USD 43.96 on October 27, 2026, with a USD 7.3 billion market capitalization and a negative price-to-earnings ratio of 12.71. Regeneron Pharmaceuticals traded at USD 816.10, with a USD 84.0 billion market capitalization and a 20.19 price-to-earnings ratio.

Stock position and next date

The combination of a lower UBS target and fresh brezosiran biomarker data leaves the October 29 results as the next concrete checkpoint for the company. The trial signal is measurable, but the program remains in Phase 1b and the company has planned a pivotal study for 2027, pending regulatory alignment. At Lang & Schwarz, the stock was trading at EUR 203.70 on October 27, 2026 at 9:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Alnylam Pharmaceuticals stock.